A database for lung cancer samples and clinical data
A Clinico-biological Database of Lung Cancers
University Hospital, Lille · NCT03387865
This study is collecting blood, tumor, and stool samples from newly diagnosed lung cancer patients to see how these samples relate to their response to standard treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Sex | All |
| Sponsor | University Hospital, Lille (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Lille) |
| Trial ID | NCT03387865 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a biological bank of samples from lung cancer patients, including blood, optional tumor tissue, and fecal samples. Samples are collected before treatment begins, during the first tumor assessment, and at the time of disease progression. Clinical data is gathered alongside these samples to identify factors associated with tumor response to standard of care treatments. The study focuses on patients with newly diagnosed lung cancer who are about to start their first line of treatment.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with a new diagnosis of lung cancer who are about to begin first-line treatment.
Not a fit: Patients with a history of prior antineoplastic treatments or contraindications to such treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of lung cancer responses to treatment, potentially leading to improved patient outcomes.
How similar studies have performed: Other studies have successfully utilized biological banking to correlate clinical outcomes with tumor biology, suggesting this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Documented new diagnosis of lung cancer by histology or cytology, or lung tumor leading to lung cancer suspicion without diagnosis for which an antineoplastic treatment is indicated * Indication of a treatment by surgery, chemotherapy, radio-chemotherapy, radiotherapy or targeted therapy as first line of lung cancer treatment * ability of the subject to follow study procedures * Age \> 18 years * Subject must have at least one measurable and/or assessable lesion in regard with RECIST 1.1 criteria * Subject is registered with a social security scheme * Subject is taken in charge at Pneumology department of Lille UH * Subject has signed an informed consent form Exclusion Criteria: * Patient with a history of treatment by antineoplastic chemotherapy, radio-chemotherapy, radiotherapy or targeted therapy, or presenting a contra indication to antineoplastic treatment administration * Subject is not willing to sign the informed consent form * Subject is not registered with a social security scheme * Subject is not francophone * Subject is deprived of his/her liberty or under trusteeship
Where this trial is running
Lille
- Hôpital Calmette, CHU — Lille, France (RECRUITING)
Study contacts
- Principal investigator: Alexis CORTOT, MD,PhD — University Hospital, Lille
- Study coordinator: Alexis CORTOT, MD,PhD
- Email: alexis.cortot@chru-lille.fr
- Phone: +33320445612
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Cancer, banking, biological sampling, tumor tissue, tumor response